Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
orlandosentinel

Orlando researchers are giving depressed, anxious people psychedelics

The study is run by Mind Medicine, a biotech pharmaceutical company seeking approval for its proprietary form of LSD.

SanFranBusTimes

Schizophrenia drug developer eyes late-stage clinical trial data this month

Reviva was founded in 2006 and has survived the double whammy of the Great
Recession and the Covid-19 pandemic.

SRC-3: CoRegen’s revolutionary approach to cancer

At the core of CoRegen’s technology is the profound understanding of SRC-3, the master regulator of the Treg genome, first discovered in the lab of renowned molecular endocrinologist Bert O’Malley at the Baylor College of Medicine.

NYT_Magazine_logo

The Mystery of My Burning Esophagus

Revolo Biotherapeutics, the company developing ‘1104, is seeking to leverage the bacterium’s ability to “reset” the immune system. If further human trials pan out, maybe we’re headed toward a new generation of drugs derived from our interactions with microbes that inhabit our bodies.

Bloomberg_Intelligence_Vanguards_Of_Health

Vanguards of Health Care by Bloomberg Intelligence: Elicio’s Broad Cancer-Vaccine Ambitions on Apple Podcasts

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.

pharmavoice

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

50 OVER 50: INNOVATION

At age 50, Alexandria Forbes founded MeiraGTx, a gene therapy company with six clinical programs and innovative technology to control genes with pills. (Gene-based medicine is typically administered via the injection of cells through a vector.)

empowered

Developing Synthetic Anti-Infectives New Class of Antibiotics to Overcome Antimicrobial Resistance with James Graham Recce Pharmaceuticals

Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective. The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of the top-performing biotech stocks in Australia.